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  SA－504， an analgetic and antispasmodic newly synthesized at Tanabe Pharmaceutical Co．
Research Laboratory， was administered intravenously to the patients having pain due to various
urological diseases or endoscopic manipulation． Over－all effectiveness rate was 87．0％．
  For pain arising from the upper urinary tract effectiveness rate was 78．9％， whereas for
pain from the lower urinary tract 91．4 ％．
  As to side effects， a transient tachycardia was seen in all the cases and palpitation in one
















使 用 薬 剤
 SA－504はpiperidine誘導体1）の一種で1．1－di－























































B  群 1尿管カテーテル挿入時使用群
     L
10 IO
C  群  膀胱攣縮時使用群 経尿道的膀胱切石術時前立腺馬道カテーテル挿塒i
3
1
D  群  膀胱鏡施行時使用群 1膀胱癌に対する膀胱部分切除術 Il  鰍定期検診嗣
 膀胱腫瘍電気凝固術施行時   1































計 31 （s7） 116 （30） 7 （13）
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